Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

FDA assigns action date for Orexo's Zubsolv NDA

Nov. 19, 2012

Catalyst Pharmaceutical reports results from phase IIb CPP-109 trial

Nov. 9, 2012

ADX-71441 shows promise in preclinical model of alcohol binge drinking

Oct. 30, 2012

DepoVax found to enhance effect of investigational cocaine vaccine

Oct. 26, 2012

Nabi Biopharmaceuticals reports results from phase II NicVAX vaccine study

Oct. 18, 2012

Reckitt Benckiser to discontinue supply of Suboxone tablets in U.S.

Sep. 28, 2012

University of Pittsburg presents new radioprotectants

Sep. 17, 2012

Pivotal pharmacokinetic study of BEMA-buprenorphine/naloxone meets objectives

Sep. 14, 2012

Orexo submits NDA for sublingual buprenorphine/naloxone product

Sep. 7, 2012

New funding supports Cellerant's development of CLT-008

Sep. 5, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...